A Novel Bioassay for the Activity Determination of Therapeutic Human Brain Natriuretic Peptide (BNP)
Figure 3
Panel A. Effect of guanylin on 293GCAC3. Guanylin is also a little peptide which could stimulate the increase of cGMP by binding GC-C. The starting concentration of rhBNP and guanylin was 2 µg/mL, serially diluted by 4 times, with the effects of these two peptides on cGMP production tested simultaneously. The data showed the guanylin had no effect on 293GCAC3 compared with rhBNP. Each point illustrates the mean of 3 replicates. Panel B. The effects of neutralizing antibody on rhBNP-induced cGMP production. rhBNP (0.5 µg/mL) was pre-incubated with rhBNP anti-serum or negative serum of serial dilutions (1∶107−1:102) at 37°C for 60 minutes. Afterwards, the mixture was analyzed for its ability of stimulating cGMP production. The results indicated that rhBNP-induced cGMP production was inhibited by the neutralizing antibody in a dose-responsive fashion. Each point illustrates the mean of 3 replicates.